Heron Therapeutics' APONVIE approved as only FDA-approved IV NK-1 antagonist for PONV prevention.

Heron Therapeutics announced the inclusion of APONVIE, an aprepitant product, in the Fifth Consensus Guidelines for the prevention of postoperative nausea and vomiting (PONV). APONVIE is recognized as the only FDA-approved IV formulation of a Neurokinin-1 antagonist indicated for the prevention of PONV in adults. The guidelines highlight the effectiveness of aprepitant alone or added to a multimodal regimen in significantly reducing the risk of PONV, and the role of long-acting antiemetic strategies in extending protection beyond the recovery room and into the home setting.